Contraceptive Progestogens and Incident Meningioma

By
Nicklas Hasselblad Lundstrøm
Mette Hjorslev Knudgaard
Michael Skaarup Pedersen
Marie Louise Schougaard Christiansen
Charlotte Wessel Skovlund
July 2, 2026
0 min

Jama Network Open

Background

Meningiomas are prevalent tumors that can lead to significant neurological complications and require invasive treatments. The higher incidence of meningiomas in women suggests a potential hormonal influence, particularly from progestogens.

Data Highlights

No specific numerical data was provided in the source material.

Key Findings

Meningioma is the most common intracranial tumor in adults, with a higher incidence in women.
Biological evidence supports a hormonal role in meningioma development, with progesterone receptors present in up to 87% of cases.
Several high-dose progestogens have been linked to an increased risk of meningioma.
Conflicting evidence exists regarding the risk associated with hormonal contraceptives, with some studies suggesting an association and others not.
This study is the first to systematically assess meningioma risk by hormonal composition across all contraceptive types.

Clinical Implications

Healthcare professionals should be aware of the potential risks associated with progestogen use in contraception, particularly in women with other risk factors for meningioma.

Conclusion

The findings highlight the need for further investigation into the relationship between progestogens and meningioma risk, particularly given the serious implications of this tumor.